SCRIP
CITELINE COMMERCIAL

30 May 2021 |

Quick Listen: Scrip's Five Must-Know Things

by Ian Haydock

In this week's podcast edition of Five Must-Know Things: a preview of the ASCO meeting; small biopharma companies thrive in the US; the world's first positive Phase III data for a microbiome therapy; Adaptimmune's plans for its T-cell receptor therapy; and Novo looks at semaglutide in early Alzheimer's.

Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by *Scrip*'s global team, in this podcast version of Five Must-Know Things.

This episode covers insights for the business week ended 28 May 2021, including: a preview of the ASCO meeting; small biopharma companies thrive in the US; the world's first positive Phase III data for a microbiome therapy; Adaptimmune's plans for its T-cell receptor therapy; and Novo looks at semaglutide in early Alzheimer's.

These and all other podcasts are available on the Informa Pharma Intelligence channel on *Apple Podcasts*, *Google Podcasts*, *SoundCloud* and *TuneIn* - and also now on *Spotify Podcasts* - and via smart speakers if one of these platforms has been set up as your default podcast provider.

Stories mentioned in this episode:

(Also see "*Five Late-Breakers To Watch For At ASCO 2021*" - Scrip, 20 May, 2021.)

(Also see "*More Small Biotechs Are Launching Drugs On Their Own*" - Scrip, 20 May, 2021.)

(Also see "*Fresh Data Pushes Microbiome Pioneer Ferring Closer To Approval Line*" - Scrip, 24 May, 2021.)

(Also see "*Adaptimmune 'Neck And Neck' For First Solid Tumor T-Cell Therapy Nod For Afami-Cel*"

© Citeline 2024. All rights reserved.

- Scrip, 21 May, 2021.)

(Also see "*Novo Nordisk's Keenly Awaited Semaglutide Trial To 'Redefine' Alzheimer's?*" - Scrip, 25 May, 2021.)

Click here to explore this interactive content online

© Citeline 2024. All rights reserved.